| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | OMVAX, INC. | 1700 MONTGOMERY ST STE 108 | SAN FRANCISCO | CA | 94111-1022 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 000 | 23 | NIH | 4/24/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $373,730 ) |
| | 2024 | 2024 | OMVAX INC | 1700 OWENS ST | SAN FRANCISCO | CA | 94158-0004 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 000 | 23 | NIH | 2/27/2024 | $336,357 |
| | 2024 | 2024 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0007 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 001 | 23 | NIH | 5/20/2024 | $37,373 |
| | 2024 | 2022 | OMVAX, INC. | 1700 MONTGOMERY ST STE 108 | SAN FRANCISCO | CA | 94111-1022 | SAN FRANCISCO | USA | R44AI124759 | A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | 000 | 4 | NIH | 6/4/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $373,730 ) |
| | 2023 | 2023 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 000 | 22 | NIH | 2/2/2023 | $373,730 |
|
| Issue Date FY: 2022 ( Subtotal = $1,373,730 ) |
| | 2022 | 2022 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R44AI124759 | A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | 000 | 4 | NIH | 5/13/2022 | $1,000,000 |
| | 2022 | 2022 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 001 | 21 | NIH | 1/14/2022 | $373,730 |
|
| Issue Date FY: 2021 ( Subtotal = $1,373,730 ) |
| | 2021 | 2021 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 002 | 20 | NIH | 9/10/2021 | $373,730 |
| | 2021 | 2021 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R44AI124759 | A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | 000 | 3 | NIH | 5/6/2021 | $1,000,000 |
|
| Issue Date FY: 2020 ( Subtotal = $1,292,679 ) |
| | 2020 | 2020 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R44AI124759 | A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups | 000 | 2 | NIH | 6/11/2020 | $1,000,000 |
| | 2020 | 2020 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R01AI046464 | Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | 003 | 19 | NIH | 9/10/2020 | $292,679 |
|
| Issue Date FY: 2019 ( Subtotal = -$35,144 ) |
| | 2019 | 2016 | OMVAX, INC. | 1700 OWENS ST STE 515 | SAN FRANCISCO | CA | 94158-0002 | SAN FRANCISCO | USA | R41AI124759 | A universal vaccine for the prevention of meningococcal meningitis in Africa | 000 | 1 | NIH | 1/7/2019 | -$35,144 |
|
| Issue Date FY: 2016 ( Subtotal = $299,970 ) |
| | 2016 | 2016 | OMVAX, INC | 1700 OWENS ST. STE 515 | SAN FRANCISCO | CA | 94158 | SAN FRANCISCO | USA | R41AI124759 | A universal vaccine for the prevention of meningococcal meningitis in Africa | 000 | 1 | NIH | 7/8/2016 | $299,970 |
|
|
